Epratuzumab Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available) Systemic Lupus Erythematosus Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) Phase 2 SL0002 Terminated NCT00113971 "Hobbs et al. Ann Rheum Dis. 2011;70(Suppl 3):319, abs THU0425. European League Against Rheumatism (EULAR) 2011. May 25-28, 2011;London, UK." Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus Phase 3 SL0003 Terminated NCT001113062005-000705-59 Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) Phase 3 SL0004 Terminated NCT003832142005-000706-31 Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus Phase 3 SL0005 Terminated NCT00382837 Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus Phase 2 SL0006 Completed NCT00383513 Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. Systemic Lupus Erythematosus Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Phase 2 SL0007 Completed NCT006243512007-002566-35 Wallace et al. Ann Rheum Dis;2014;73(1);183-190. Systemic Lupus Erythematosus Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Phase 2 SL0008 Completed NCT006608812007-002589-37 Wallace, D. J. et al. Arthritis Care Res (Hoboken);2016;68;4;534-543 Systemic Lupus Erythematosus Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1) Phase 3 SL0009 Completed NCT012623652010-018563-41 LINKLINK Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 Systemic Lupus Erythematosus Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2) Phase 3 SL0010 Completed NCT012617932010-018565-26 LINKLINK Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 Systemic Lupus Erythematosus Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4) Phase 3 SL0012 Completed NCT014085762010-020859-30 LINKLINK Systemic Lupus Erythematosus Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Phase 2 SL0027 Completed NCT01534403
